Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Cash from Investing Activities: 2010-2021

Historic Cash from Investing Activities for Neurocrine Biosciences (NBIX) over the last 11 years, with Dec 2021 value amounting to $23.7 million.

  • Neurocrine Biosciences' Cash from Investing Activities rose 116.05% to $23.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$130.2 million, marking a year-over-year decrease of 3275.61%. This contributed to the annual value of -$126.8 million for FY2024, which is 72.85% up from last year.
  • According to the latest figures from Q4 2021, Neurocrine Biosciences' Cash from Investing Activities is $23.7 million, which was up 118.78% from -$126.2 million recorded in Q3 2021.
  • In the past 5 years, Neurocrine Biosciences' Cash from Investing Activities registered a high of $93.4 million during Q2 2020, and its lowest value of -$213.3 million during Q2 2017.
  • Over the past 3 years, Neurocrine Biosciences' median Cash from Investing Activities value was $11.7 million (recorded in 2019), while the average stood at -$28.1 million.
  • In the last 5 years, Neurocrine Biosciences' Cash from Investing Activities tumbled by 1,262.50% in 2017 and then skyrocketed by 31,233.33% in 2020.
  • Over the past 5 years, Neurocrine Biosciences' Cash from Investing Activities (Quarterly) stood at -$59.4 million in 2017, then slumped by 78.87% to -$106.2 million in 2018, then plummeted by 56.44% to -$166.2 million in 2019, then grew by 11.13% to -$147.7 million in 2020, then skyrocketed by 116.05% to $23.7 million in 2021.
  • Its Cash from Investing Activities stands at $23.7 million for Q4 2021, versus -$126.2 million for Q3 2021 and -$90.8 million for Q2 2021.